NCT06954636 Prognostic Potential of Olfactory Function in Glioblastoma: a Prospective Observational Study
| NCT ID | NCT06954636 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Sied Kebir |
| Condition | Glioblastoma Multiforme, Adult |
| Study Type | OBSERVATIONAL |
| Enrollment | 128 participants |
| Start Date | 2023-05-03 |
| Primary Completion | 2027-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 128 participants in total. It began in 2023-05-03 with a primary completion date of 2027-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The study aims to investigate the prognostic significance of olfactory function in patients with glioblastoma. We are examining olfactory function at various points during therapy and correlating the results with survival data. In addition, neurocognitive tests will be carried out to correlate the results of olfactory function with the patient's cognitive abilities. Investigations into the quality of life and psychological condition of the patients are also performed. In addition to the cohort of glioblastoma patients, there is a control cohort without tumor disease in which the olfactory testing is also carried out in order to have a comparison.
Eligibility Criteria
Inclusion Criteria: * At least 18 years of age * Newly-diagnosed glioblastoma (IDH wild-type) * Never received prior chemotherapy * Never received radiotherapy to the head or neck before * KPS ≥ 70 * No history of severe head or brain trauma requiring ICU admission or classified as Glasgow Coma Scale grade 3 * No respiratory infection at the time of inclusion * No significant aphasia Exclusion Criteria: * Presence of Neurodegenerative diseases (e.g. Parkinson's disease, Alzheimer's disease, Huntington's disease, Korsakoff's syndrome, Pick's disease, Shy-Drager syndrome) * History of invasive tumors or surgery in the head or neck area, except for surgeries for non-invasive skin tumors (e.g. basal cell carcinomas) * Permanent olfactory impairment following infections (e.g., influenza, coronavirus) * Conditions that, in the examiner's judgment, could interfere with the participant's study compliance (e.g., schizophrenia) * Language barriers likely to interfere with participation or comprehension of study procedures.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06954636 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Glioblastoma Multiforme, Adult. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06954636 currently recruiting?
Yes, NCT06954636 is actively recruiting participants. Contact the research team at christoph.oster@uk-essen.de for enrollment information.
Where is the NCT06954636 trial being conducted?
This trial is being conducted at Essen, Germany, Münster, Germany.
Who is sponsoring the NCT06954636 clinical trial?
NCT06954636 is sponsored by Sied Kebir. The trial plans to enroll 128 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.